How to Determine Product Classification for Medical Device Registration in Indonesia

Published: 2026-07-10 14:11 | Updated: 2026-07-10 14:11

To determine product classification for medical device registration in Indonesia, companies should first confirm the target country, product risk level, applicable regulatory pathway, and existing documentation basis. Then assess technical files, quality management system, labeling and instructions for use, local agent, clinical evidence, and post-market maintenance requirements. AIMEILI recommends conducting a documentation gap assessment before formal submission to avoid prolonged project timelines due to unclear classification, documentation, or authorization arrangements.

Key Takeaways

• Confirm target country, product risk level, applicable regulatory pathway, and existing documentation.
• Assess technical files, QMS, labeling/IFU, local agent, clinical evidence, and post-market maintenance.
• Conduct a documentation gap assessment before submission to avoid delays.
• For Chinese manufacturers, determine if NMPA, CE, FDA, ISO 13485, or other market documents can be reused.
• Indonesia registration affects technical files, authorized representative, importer cooperation, label language, QMS certificates, and change maintenance.
• Avoid focusing only on "what documents to submit" to prevent deficiencies in model coverage, evidence consistency, label claims, and certificate control.
• Plan within GHWP member states and multi-country access strategy using a reusable core technical file.

Applicable Scenarios and Core Issues

Companies searching for "how to determine product classification for medical device registration in Indonesia" typically want to know whether their existing documentation can support an Indonesian submission, whether a local agent or authorized representative is needed, why timelines may be extended, and which issues could affect launch plans. This question often involves product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America simultaneously, answering the process for one country alone is insufficient. A more valuable approach is to first create reusable versions of core technical files, QMS certificates, performance verification, clinical evidence, and labeling/IFU, then localize them according to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the product's intended use, mechanism of action, use scenario, body contact method, duration of use, whether it is sterile, whether it has an energy source, and whether it contains software or has IVD attributes. Then determine the risk level and submission pathway. If the pathway is incorrect, subsequent translation, notarization, authorization, testing, and supplementary documents will all be misdirected.

For Indonesia projects, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who handles regulatory communication, who manages import and post-market events, who triggers changes, and who maintains renewal documents. If these issues are handled vaguely in commercial contracts, they can easily affect market control later.

Documents and Evidence

Common documents include product description, model/specification matrix, intended use, risk classification rationale, ISO 13485 or applicable QMS certificate, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labeling/IFU, authorization documents, existing registration certificates, manufacturer's declaration, and post-market surveillance data.

The key to document quality is not quantity but consistency. Labeling claims, test report model coverage, clinical evidence scope, risk management conclusions, label warnings, and registration application form information must support each other. Regulatory authorities focus on whether the product is safe, effective, and traceable for its intended use, not on how many documents are uploaded.

Common Mistakes

The most common problem is treating registration as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Translating NMPA documents directly and submitting them without rearranging evidence according to the Indonesian pathway.
• Having too many model/specifications but insufficient coverage in test reports, clinical evidence, or labeling.
• Selecting a local agent solely based on sales cooperation without clarifying regulatory responsibilities, certificate control, and post-market maintenance duties.
• Inconsistencies between labels, IFU, promotional materials, and registration claims, leading to deficiencies or post-market compliance risks.
• Failing to plan for multi-country document reuse in advance, resulting in repeated preparation for each country and increased cost and timeline.

Preparation Checklist for Companies

Before starting the project, companies should use an internal checklist to confirm the documentation basis, avoiding the discovery of critical evidence gaps after submission.

• Compile a target product list, model/specification matrix, and intended use statements.
• Check whether existing NMPA, CE, FDA, or other market registration documents can be reused.
• Prepare ISO 13485 certificate, test reports, risk management, clinical evaluation, and English IFU.
• Confirm the responsibilities, costs, certificate control, and exit mechanism of the local agent or authorized representative.
• Establish a target country gap assessment table, specifying content that needs additional testing, translation, notarization, or supplementary declarations.

AIMEILI's Perspective

AIMEILI recommends that companies not view Indonesia registration as a one-time document submission, but manage it as an overseas market access project. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first, then converting according to country requirements, is usually faster, more stable, and more conducive to subsequent changes and renewals than ad hoc supplementation per country.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, consistency of the documentation evidence chain; third, regulatory responsibility boundaries of local partners. If these three are unclear, even if documents appear abundant, the project may still encounter repeated deficiencies, agent communication issues, and post-market maintenance challenges.

Frequently Asked Follow-up Questions

Can domestic documents be used directly for Indonesia registration?

Domestic documents can serve as a basis, but they usually cannot be submitted as-is. Companies need to adjust the document structure, language, labeling, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start the gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustments, and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent typically participates in registration communication, changes, renewals, and post-market event handling. Unclear rights and responsibilities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing such registration projects, companies should establish a project ledger to manage the product list, model/specifications, registration pathway, document responsible persons, translation status, testing status, local agent communication records, and expected submission time in a single table. This allows timely identification of document gaps and helps management determine whether the project will affect launch plans.

For companies with existing registrations in multiple countries, an evidence reuse matrix should also be established to clarify which documents can serve as core evidence and which must be reissued or supplemented according to country requirements. In particular, labeling/IFU, clinical evaluation, risk management, performance verification, and QMS certificates must remain version-consistent.

• Confirm target markets and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify local agent and certificate control.
• Track translation, notarization, testing, and deficiency status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, QMS documents are not isolated certificates. Regulatory authorities typically check the consistency among manufacturer name, production address, product scope, certificate validity, applicable standards, and technical files. If the ISO 13485 certificate scope does not match the submitted product, or if the production address, model/specifications, or IFU version is inconsistent with test reports, even if a large number of documents are prepared, supplementary explanations may be required.

Companies should establish an evidence consistency checklist before submission, mapping product name, model/specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labeling/IFU version, and QMS certificate one by one. This action may seem basic, but it can significantly reduce the probability of deficiencies, especially for projects submitted simultaneously to multiple GHWP member states or for multiple product series.

Localization and Agent Responsibilities

Indonesia registration projects typically involve arrangements with a local agent, authorized representative, importer, or registration holder. Companies need to confirm in advance whether the local partner is only responsible for submitting documents or also undertakes regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labeling/IFU and authorization documents cannot be simply translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already have CE, FDA, NMPA, or other market documents, the focus of localization is to convert reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many companies invest heavily in obtaining the certificate but neglect post-market maintenance. Subsequently, if there is a production address change, model expansion, IFU update, or agent replacement, the certificate may become disconnected from market sales.

AIMEILI recommends that companies incorporate this issue into annual international registration plan management: first clarify target market priorities, then establish a reusable document package and country gap list, and finally schedule submission, deficiency response, post-market maintenance, and renewal milestones. The value of this approach is not only to improve registration efficiency for a single country, but more importantly to help companies develop replicable overseas compliance capabilities, reducing the cost of starting from scratch each time they enter a new market.

Continue Reading

• Previous: How to Prepare Registration Documents for Medical Device Registration in Indonesia?
• Next: How to Organize Technical Files for Medical Device Registration in Indonesia?
• Recommended Reading:
  • How to Prepare Registration Documents for Medical Device Registration in Malaysia?
  • How to Determine Product Classification for Medical Device Registration in Malaysia?
  • How to Organize Technical Files for Medical Device Registration in Malaysia?
  • How to Localize Labeling and IFU for Medical Device Registration in Malaysia?
  • How to Prepare Clinical Evaluation Documents for Medical Device Registration in Malaysia?
  • Can Test Reports Be Reused for Medical Device Registration in Malaysia?

Content Review and Scope

Content Author: AIMEILI Regulatory Editorial Team

Professional Review: AIMEILI Medical Device International Registration Project Team

Source Principle: Priority is given to official regulatory authorities, international organizations, standards organizations, and public regulatory information; industry media and project experience are used only as auxiliary judgment.

Scope: This article is intended for preliminary understanding, document preparation, and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions, or legal advice.